BiotechTube
Akribion Therapeutics

Akribion Therapeutics

Munich, Germany· Est.
akribion-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Akribion Therapeutics is an early-stage, Munich-based biotech that exited stealth in February 2025 with an €8 million seed financing round. The company is developing a unique platform technology centered on G-dase® E, a programmable cytotoxic nuclease that depletes cells with single-nucleotide specificity guided by RNA sequences. This approach, initially targeting HPV+ head and neck cancer, has broad potential applications across oncology, autoimmune diseases, fibrosis, and infectious diseases. The company is led by an experienced team with roots in BRAIN Biotech AG, where the core technology was discovered.

OncologyAutoimmune DiseasesFibrosisInfectious Diseases

Technology Platform

Proprietary G-dase® E, an RNA-guided nuclease enzyme platform for programmable cell depletion. The system uses a guide RNA (gRNA) to recognize specific intracellular RNA sequences, activating the cytotoxic nuclease only in target cells with single-nucleotide specificity.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The platform's modularity allows rapid retargeting to new diseases by simply changing the guide RNA, enabling swift pipeline expansion.
The initial focus on HPV+ head and neck cancer addresses a clear unmet need with a well-defined viral RNA target, providing a streamlined path to initial clinical proof-of-concept.
Broad potential exists in autoimmune diseases and fibrosis, where precise depletion of pathogenic cell types could be transformative.

Risk Factors

The novel G-dase E platform is unproven in humans, with key risks around in vivo delivery efficiency, potential off-target effects, and overall therapeutic efficacy.
As a preclinical company with €8M in seed funding, it faces significant execution and financial risk in advancing to the clinic amidst competitive and potentially challenging financing environments.

Competitive Landscape

Akribion competes in the targeted cell therapy space against modalities like Antibody-Drug Conjugates (ADCs), T-cell engagers, and CAR-T therapies. Its unique differentiator is the RNA-guided mechanism for single-nucleotide specificity and a potentially faster retargeting process compared to protein-based biologics. It also faces competition from other next-generation nuclease and RNA-targeting platforms.

More companies in Cell & Gene Therapy →More companies in Germany →